NCT05158062 2022-04-26Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerSaitama Medical University International Medical CenterPhase 2 Unknown35 enrolled